CAR-T Yields High Responses in ALL Across Trials

(MedPage Today) -- Eighty percent of patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL) achieved complete remission after treatment with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, pooled data from 35 different...